$14.2 M

NVIV Mkt cap, 18-Mar-2019
InVivo Therapeutics Net income (Q3, 2018)-3.2 M
InVivo Therapeutics EBIT (Q3, 2018)-2.1 M
InVivo Therapeutics Cash, 30-Sep-201819.7 M

InVivo Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

14.0m13.5m20.2m21.5m12.9m

Prepaid Expenses

1.1m184.0k451.0k

Inventories

20.1k

Current Assets

14.6m15.0m20.7m33.9m13.8m

PP&E

2.3m1.6m938.0k510.0k

Total Assets

17.1m16.7m21.8m34.8m14.0m

Accounts Payable

899.3k569.0k521.0k1.0m988.0k

Current Liabilities

2.3m9.2m3.3m4.8m3.1m

Total Liabilities

4.2m10.8m4.9m5.8m3.9m

Common Stock

1.0k1.0k1.0k

Additional Paid-in Capital

94.8m106.2m150.5m186.0m194.0m

Retained Earnings

(100.3m)(133.6m)(157.0m)(183.9m)

Total Equity

12.9m5.9m16.9m28.9m10.1m

EPS

0.81.30.8

Financial Leverage

1.3 x2.8 x1.3 x1.2 x1.4 x

InVivo Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(38.8m)(18.3m)(33.3m)(23.4m)(26.7m)

Depreciation and Amortization

740.7k752.0k689.0k553.0k395.0k

Accounts Payable

(253.3k)(330.0k)(48.0k)489.0k(23.0k)

Cash From Operating Activities

(14.9m)(15.3m)(16.3m)(16.7m)(19.7m)

Purchases of PP&E

(748.5k)(47.0k)(5.0k)(107.0k)(65.0k)

Cash From Investing Activities

(748.5k)(2.0k)(5.0k)(6.5m)11.5m

Long-term Borrowings

(18.0k)

Cash From Financing Activities

16.8m14.8m23.1m29.8m(383.0k)

Net Change in Cash

(521.0k)1.5m6.5m

Interest Paid

125.3k132.0k121.0k103.0k71.0k

InVivo Therapeutics Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information

InVivo Therapeutics Operating Metrics

FY, 2016

Facilities

1

Patents (Foreign)

8

Patents (US)

8

Patents Pending

12
Report incorrect company information

InVivo Therapeutics Employee Rating

2.82 votes
Culture & Values
2.8
Work/Life Balance
5.0
Senior Management
2.8
Salary & Benefits
3.4
Career Opportunities
2.5
Source